Oramed Pharmaceuticals Inc. — Investor Relations & Filings
Filings indexed
1,576
across all filing types
Latest filing
2026-05-19
Interim / Quarterly Rep…
Country
US
United States of America
Listing
TA
ORMP
Oramed Pharmaceuticals Inc. is a clinical-stage company focused on developing oral drug delivery systems for medications that are typically administered via injection. The company's core technology is its proprietary Protein Oral Delivery (POD™) platform, which is designed to protect therapeutic proteins from enzymatic degradation in the gastrointestinal tract and enhance their absorption into the bloodstream. Oramed's lead product candidate is an oral insulin capsule (ORMD-0801) for the treatment of diabetes. The company's pipeline also includes an oral GLP-1 analog capsule (ORMD-0901) for type 2 diabetes. Oramed aims to improve patient compliance, comfort, and therapeutic outcomes by converting injectable treatments into oral formulations.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| QUARTERLY REPORT | 2026-05-19 | English | |
| 4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer) | 2026-03-18 | English | |
| 4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer) | 2026-03-18 | English | |
| 4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer) | 2026-03-18 | English | |
| 4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer) | 2026-03-18 | English | |
| 8-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer) | 2026-02-20 | English |
Browse filings by year
25 years- 2026 33 filings
- 2025 80 filings
- 2024 124 filings
- 2023 114 filings
- 2022 131 filings
- 2021 172 filings
- 2020 112 filings
- 2019 133 filings
- 2018 85 filings
- 2017 96 filings
- 2016 32 filings
- 2015 38 filings
- 2014 64 filings
- 2013 54 filings
- 2012 62 filings
- 2011 43 filings
- 2010 44 filings
- 2009 27 filings
- 2008 40 filings
- 2007 31 filings
- 2006 20 filings
- 2005 19 filings
- 2004 14 filings
- 2003 7 filings
- 2002 1 filing
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 46559696 | QUARTERLY REPORT | 2026-05-19 | English | ||
| 32980125 | 4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer) | 2026-03-18 | English | ||
| 32980123 | 4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer) | 2026-03-18 | English | ||
| 32980115 | 4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer) | 2026-03-18 | English | ||
| 32980116 | 4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer) | 2026-03-18 | English | ||
| 32888835 | 8-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer) | 2026-02-20 | English | ||
| 28373831 | SCHEDULE 13G/A Filing | 2026-02-09 | English | ||
| 28373838 | 4 Filing | 2026-01-29 | English | ||
| 28373832 | SCHEDULE 13D Filing | 2026-01-29 | English | ||
| 28373823 | 4 Filing | 2026-01-29 | English | ||
| 28373735 | 4 Filing | 2026-01-29 | English | ||
| 28373726 | 4 Filing | 2026-01-29 | English | ||
| 13193894 | FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP - KIDRON MIRIAM | 2026-01-22 | English | ||
| 13193893 | FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP - KIDRON MIRIAM | 2026-01-22 | English | ||
| 28373796 | 4 Filing | 2026-01-21 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AC Immune SA
Biopharmaceutical firm developing precision medicine for ne…
|
ACIU | CH | Manufacturing |
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
Oramed Pharmaceuticals Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/6965/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=6965 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=6965 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=6965 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 6965}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Oramed Pharmaceuticals Inc. (id: 6965)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.